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Endocrine Therapy for Prostatic Cancer
Can Replace Orchiectomy and Estrogens
By treating patients who have advanced prostate cancer with
a drug that changes endocrine function, physicians in the UT
MDAH Department of Urology have produced remissions and
promoted well-being in patients who have traditionally had to
face the radical side effects of surgical castration and estrogen
therapy.
Since January 1983, Andrew C. von Eschenbach, M.D.,
department chairman, has led a study of the use of buserelin,
a luteinizing hormone-releasing hormone (LHRH) agonist, in
22 men between the ages of 59 and 80. All had stage D prostate
cancer that had metastasized.
Tests to establish tumor stage and identify metastasis
included biopsy, hematologic and biochemical blood assays,
urinalysis, radionuclide bone scan, bone radiographs , and
lymphangiography or computed tomography (CT) scan, or both.
The patients' general physical condition and endocrine
function were evaluated at the beginning and during therapy.
Clinical monitoring in collaboration with Naguib A. Samaan,
M.D., Department of Endocrinology, and Herbert A. Fritsche,
Ph.D., Department of Laboratory Medicine, continues for
patients who are still taking buserelin, although entry into the
formal study period has ended.
Buserelin has not yet been approved by the Food and Drug
Administration for general clinical use, but a similar drug,
luprolide (Lupron), is now on the market after being tested at
other resesearch centers. It is prescribed by MDAH physicians
for some patients with prostate cancer who are not in the
buserelin study.
During the first week of therapy, the patients received 1,500 µg
of buserelin daily, administered subcutaneously in three doses
of 500 µg each, after which the daily dose has been 200 µg.
In a recent interview, von Eschenbach described the results
of the study. "Buserelin treatment resulted in a favorable
response in all 22 patients," he said. "Nineteen patients had
bone scans that were considered positive for metastatic disease,
and 13 of these patients demonstrated improvement. Thirteen
patients had lymph node metastases, which regressed in eight
patients. Among 17 patients who showed abnormal prostatic
acid phosphatase (PAP) secretion, 15 patients improved, and
in 12 of these the PAP levels returned to normal."
Today, nine patients are still in the study. The others suffered
relapses and are being treated with chemotherapy. Six patients
have died, including two who died from causes other than
prostate cancer.

Endocrine therapy, von Eschenbach said, is not curative, nor
is any other therapy so far attempted for patients in advanced
stages of the disease. But endocrine therapy promotes remissions. It usually alleviates the severe pain of disseminated prostatic cancer in the bones and may relieve problems of urination
caused by urethral obstruction, thus improving the patients' performance status and emotional well-being.
The major advantage of this kind of endocrine therapy, von
Eschenbach said, is that buserelin and similar drugs have made
orchiectomy and estrogen therapy-which caused gynecomastia
in most patients-no longer obligatory. The problems of loss
of libido and impotence remain, because all endocrine treatments for prostate cancer exert their effects by withdrawing
testosterone from these hormone-sensitive tumors (Fig. I).

Most Prevalent Cancer in Men
The buserelin results have an importance beyond their numbers, von Eschenbach explained, because cancer of the prostate
is an example of the diagnostic and treatment problems clinicians face in dealing with many other forms of neoplasia.
continued on page 2
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Fig. 1. Mechanisms of endocrine regulation. The prostate is
directly affected by androgens produced principally by the tes tis. These various regulatory mechanisms provide numerous
options for endocrine control strategies. ACTH, adrenocorticotropic hormone; FSH , follicle-stimulating hormone; LH, luteinizing hormone. (Reproduced with permission from Smith,
D. R.: General Urology, 11th Ed. Copyright 1984 by Lange
Medical Publications, Los Altos, CA.)
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Although it is a disease of aging and rarely occurs in men
younger than 50, it is one of the most common cancers in men.
About 75,000 cases of prostate cancer are expected to be diagnosed annually, and about 24,000 deaths occur yearly as a result
of the disease.
Prostate cancers have differing biologic characteristics and
malignant potential, ranging from the slow-growing, confined
tumor to the type that grows rapidly and quickly develops
aggressive metastasis. In the mid-range is the prostatic tumor
that grows slowly for years and then suddenly develops sufficient numbers of cell clones to disseminate to the bones and
lympathic system.
The disease was once considered rare because it is so difficult
to diagnose. Compared to the number of prostate cancers diagnosed, three to eight times more cases are not found until
patients undergo a prostatectomy for benign disease or during
autopsy examinations.
A comparable disease is breast cancer in women, but this
occurs earlier in life and is perhaps easier to diagnose at earlier
stages because of public and medical education about the disease. There are striking similarities between breaat and prostate
cancer; for example, both are adenocarcinomas for which hormonal treatments are used, von Eschenbach said.
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Because of the difficulties of diagnosing prostatic carcinoma
and the heterogeneity of its expression, von Eschenbach and
his colleagues have called for a new look at the incidence,
development, diagnosis, therapeutic decisions, and evaluat ion
of results-a new effort of which the buserelin study is a part.

Epidemiologic Factors
Epidemiologic studies have shown, he said, that genetic
factors (Fig. 2) may play a role because cancer of the prostate
is more common among American black men than white men,
and because Oriental peoples in their home countries have a
lower incidence of clinically diagnosed disease. The latter finding has also led to the suggestion that a diet low in fat and rich
in vitamins A and D may play a part in modulating the incidence and virulence· of malignant prostatic disease. Environmental factors may have an influence as well, since some studies
have linked work in the rubber, textile, and fert ilizer industries
to higher rates of prostate cancer.
That hormones have a role is certain, although their exact
mechanism of action is not known and the responsible endocrine factors have not been identified. The appearance of
prostate cancer after age 50 suggests strongly , however, that
development of the cancer is related to changes with age in
the male endocrinologic environment, when serum testosterone declines and the ratio of estrogen to testosterone rises. The
fact that prostatic carcinoma responds to androgen deprivation
supports a direct relationship between the tumor and hormonal
change.

Pathologic Features
As von Eschenbach explained, the formation of malignant
tissue begins in the stem cells of the acinar prostatic epithelicontinued on page 3
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Fig. 2. Epidemiologic influences. Many factors may contribute
to the development of cancer of the prostate and affect its
biologic behavior. (Reproduced with permission from von
Eschenbach, A. C.: Cancer of the prostate, in Hickey, R. c.
et al., eds.: Current Problems in Cancer. Copyright 1981 by
Year Book Medical Publishers, Chicago.)
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Fig. 3. St aging of prostate cancer . Based on extent of tumor,
various modifications in the A, B, C, and D types of prostate
cancer have been proposed and are currently in use, but the
definition of t hese subdivisions is not uniform. (Reproduced
with permission from von Eschenbach, A. C.: Cancer of the
prostate , in Hickey, R. C. et al., eds.: Current Problems in
Cancer. Copyright 1981 by Year Book Medical Publishers,
Chicago .)

continued from page 2
um. The degree of abnormality varies, so that some tumors are
difficult to distinguish from normal prostate tissue, except that
the glands are small and crowded. In others the cellular structure will be strikin gly altered, with the tissue forming a solid
pattern in which the glands cannot be distinguished. Since structural differences may occur in parts of the same tumor, the grading of prostate cancer is often difficult and confusing.
Fig. 3 is a graphic interpretation of tumor stages. At this hospital, von Eschenbach explained, stage is based on extent of disease, and tumor grade is based on percentage of gland formation within the primary tumor.

Fig. 4. Trilogy of the clinical manifestations of prostate cancer.
(Reproduced with permission from Johnson, D. E., and von
Eschenbach, A. C.: Prostatic carcinoma: A trilogy of clinical
expressions. Southern Medical Journal 73( 10): 1304, 1980.)

spine or pelvis. A general feeling of illness, fatigue, and weight
loss are nonspecific clinical indications of the disease.
Fig. 4 represents the clinical manifestations, which von Eschenbach summarized as follows:
•

Changes in the size, shape, or consistency of the prostate.
A hard discrete nodule in the prostate of a man older than
50 has an about 50% chance of being a malignant tumor.

•

Metastases to the bones manifested by areas of tenderness
on palpation. Sometimes lymphadenopathy is detected by
palpating the inguinal region, the pelvic side wall, or the
supraclavicular fossa.

When a patient is suspected of having cancer of the prostate,
von Eschenbach recommended these procedures:
•

Biopsy of the gland with histologic examination of tissue
obtained by needle biopsy of the prostate or, at times, by
transurethral resection.

•

Laboratory studies including complete blood count :3-nd
serum biochemical profile. Determination of the serum level
of acid phosphatase is most important because of the
association of elevated levels of serum acid phosphatase and
advanced prostatic cancer.

•

Radiologic studies including chest radiography, radiographs
of the lower spine and pelvis, and radionuclide bone scan.

•

Lymphangiography for patients suspected of having nodal
disease .

•

CT complementary to lymphangiography. Although CT
scans do not show intranodal architecture, they reveal
enlarged nodes completely replaced by the tumor. Unfortunately, both CT scans and lymphangiograms tend to
understage patients with nodal disease.

Clinical Findings
The tumor h as few warning signs because it does not progress
in predictable fashion from microscopic disease to regional
spread to distant metastasis. That is why, in many patients,
symptoms of metastasis may occur before the disease is diagnosed in the prostate gland. Benign disease usually causes
obstructive voiding symptoms in older men. Prostate cancer,
however, originates in the periphery of the gland and impairs
micturition only after the tumor has grown quite large. Most
patients do not experience pain on ejaculation or have problems
of sexual function but, according to von Eschenbach,
hematospermia and hematuria, which may accompany benign
hypertrophic hyperplasia, may lead to the detection of
unsuspected cancer. The presence of these symptoms in patients
older than 50 years should always alert physicians to do a
careful assessment .
This is true also for elderly men who may complain of persistent bone pain, which may be multifocal or restricted to the
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Endocrine Therapy.
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Fig. 5. Decision matrix for selecting therapy. Tumor grade is
correlated with increasing malignant potential, and tumor stage
is correlated with increasing tumor burden. TURP, transurethral
resection of the prostate. (Reproduced with permission from
Smith, D. R.: General Urology, 11th Ed. Copyright 1984 by
Lange Medical Publications, Los Altos, CA.)

Treatment
Dr. von Eschenbach summarized treatment, according to the
stages of prostatic cancer, as transurethral resection of the
prostate; radical prostatectomy; interstitial radiation, externalbeam megavoltage radiation, or a combination of the two;
endocrine therapy; and chemotherapy (Fig. 5).
He has emphasized endocrine therapy because about one-third
of patients already have clinical evidence of metastasis at the
time of diagnosis, when total eradication is impossible by
currently available techniques.
"Charles Huggins won the Nobel Prize in 1966," he said, "for
his discovery in the 1940s of the hormonal mechanisms of
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prostate cancer, and his work is still the basis of our endocrine
treatment. But we are now learning that we can substitute new
drugs for the castration and estrogen therapy that can have such
severe physical and emotional consequences.
" The di ease is so common, yet so often hidden for years ,
that we must find methods of earlier diagnosis, and more effective treatment for cure. To accomplish this we must learn more
about this tumor'~ biology and behavior." ~
(Physicians who desire additional information may write Andrew
C. von Eschenbach, M .D., Department of Urology , MDAH
Box 110, The University of Texas M. D. Anderson Hospital and
Tumor Institute, 6723 Bertner Avenue, Houston, Texas

77030-ED.)
The Cancer Information Service provides up-to-date information and literature about cancer via toll-free telephone lines.
Patients can reach CIS at:

1-800-4-CANCER toll-free in Texas
and 792-3245 in Houston
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